A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Stopped early · Phase 3
Conditions studied: Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
In brief
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Patients may be eligible to crossover from physician's choice chemotherapy to MEK162 if they meet certain inclusion criteria including centrally confirmed disease progression. Approximately 360 patients from North America, Europe and Australia will be enrolled in this study.
Key facts
- Study ID
- NCT01849874
- Run by
- Pfizer
- People needed
- 341
- Starts
- 2013-06-27
- Expected to finish
- 2022-08-23
- Last updated by the study team
- 2023-10-30
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Associated Retina Consultants, Ltd. — Phoenix, Arizona, United States
- Oncology Research Associates, PLLC d/b/a Pinnacle Oncology Hematology — Scottsdale, Arizona, United States
- Keck Hospital of USC — Los Angeles, California, United States
- LAC & USC Medical Center — Los Angeles, California, United States
- USC Healthcare Consultation Center 1 — Los Angeles, California, United States
- USC Healthcare Consultation Center 2 — Los Angeles, California, United States
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- Admin.Office/Study Supplies Mailing Address: UCLA Medicine Hematology-Oncology — Los Angeles, California, United States
- Doris Stein Research Center Building — Los Angeles, California, United States
- University of California Los Angeles, Hematology-Oncology Clinic — Los Angeles, California, United States
- Gynecologic Oncology Associates — Newport Beach, California, United States
- University of California, Irvine/UC Irvine Health — Orange, California, United States
- UCLA Hematology/Oncology Clinic - Santa Monica — Santa Monica, California, United States
- UCLA Hematology Oncology Clinic Santa Clarita — Valencia, California, United States
- UCLA Hematology - Oncology Clinic - Westlake Village — Westlake Village, California, United States
- Rocky Mountain Lions Eye Institute — Aurora, Colorado, United States
- University of Colorado Cancer Center — Aurora, Colorado, United States
- University of Colorado Denver, University of Colorado Cancer Center — Aurora, Colorado, United States
- Smilow Cancer Hospital at Yale-New Haven — New Haven, Connecticut, United States
- Eye Physicians of Central Florida — Maitland, Florida, United States
- Florida Hospital — Orlando, Florida, United States
- Florida Hospital Cancer Institute — Orlando, Florida, United States
- Eye Physicians of Central — Orlando, Florida, United States
- University of Arizona Cancer Center — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.